Beta Bionics (NASDAQ:BBNX) Stock: Insider Mark Hopman Sells 775 Shares

Beta Bionics, Inc. (NASDAQ:BBNX – Get Free Report) insider Mark Hopman sold 775 shares of the firm’s stock in a transaction on Monday, November 16th. The shares were sold at an average price of $16.22, for a total value of $12,570.50. Following the completion of the sale, the insider owned 54,143 shares of the company’s stock, valued at approximately $878,199.46. This trade represents a 1.41% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Mark Hopman also recently made the following trade(s):

  • On Monday, October 26th, Mark Hopman sold 821 shares of Beta Bionics stock. The shares were sold at an average price of $20.00, for a total value of $16,420.00.
  • On Wednesday, October 14th, Mark Hopman sold 775 shares of Beta Bionics stock. The stock was sold at an average price of $17.35, for a total transaction of $13,446.25.
  • On Thursday, October 1st, Mark Hopman sold 370 shares of Beta Bionics stock. The shares were sold at an average price of $18.96, for a total transaction of $7,015.20.
  • On Wednesday, September 16th, Mark Hopman sold 30,779 shares of Beta Bionics stock. The shares were sold at an average price of $20.13, for a total transaction of $619,581.27.
  • On Wednesday, September 9th, Mark Hopman sold 36,870 shares of Beta Bionics stock. The stock was sold at an average price of $18.46, for a total transaction of $680,620.20.
  • On Wednesday, September 2nd, Mark Hopman sold 5,327 shares of Beta Bionics stock. The stock was sold at an average price of $19.11, for a total transaction of $101,798.97.

Beta Bionics Trading Down 2.6%

Shares of Beta Bionics stock traded down $0.39 during midday trading on Wednesday, reaching $14.33. The company had a trading volume of 1,376,418 shares, compared to its average volume of 1,176,370. The company has a market capitalization of $779.12 million, a price-to-earnings ratio of -7.79 and a beta of 3.44. Beta Bionics, Inc. has a 1-year low of $8.80 and a 1-year high of $32.71. The stock has a fifty day simple moving average of $18.29 and a 200 day simple moving average of $14.86.

Beta Bionics (NASDAQ:BBNX – Get Free Report) last announced its quarterly earnings data on Tuesday, October 27th. The company reported ($0.52) earnings per share for the quarter, topping the consensus estimate of ($0.53) by $0.01. Beta Bionics had a negative return on equity of 27.33% and a negative net margin of 65.31%. The firm had revenue of $35.51 million during the quarter. Sell-side analysts expect that Beta Bionics, Inc. will post -2.04 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. BlackRock Inc. bought a new position in shares of Beta Bionics during the second quarter worth about $52,340,000. Eversept Partners LP lifted its stake in Beta Bionics by 108.6% in the 1st quarter. Eversept Partners LP now owns 1,414,838 shares of the company’s stock valued at $14,177,000 after acquiring an additional 736,576 shares in the last quarter. Bank of America Corp DE acquired a new position in Beta Bionics during the 2nd quarter worth approximately $8,566,000. Perceptive Advisors LLC grew its stake in shares of Beta Bionics by 39.8% during the 1st quarter. Perceptive Advisors LLC now owns 842,944 shares of the company’s stock worth $8,446,000 after acquiring an additional 240,000 shares in the last quarter. Finally, Bruce & Co. Inc. bought a new position in shares of Beta Bionics during the 1st quarter worth approximately $5,518,000.

Analyst Ratings Changes

A number of brokerages have issued reports on BBNX. Wells Fargo & Company started coverage on Beta Bionics in a report on Wednesday, September 23rd. They set an “overweight” rating and a $28.00 target price on the stock. Piper Sandler reissued an “overweight” rating and set a $24.00 price objective (up from $20.00) on shares of Beta Bionics in a research note on Wednesday, October 28th. Jefferies Financial Group started coverage on shares of Beta Bionics in a report on Monday, October 12th. They set a “buy” rating and a $30.00 price objective for the company. Truist Financial boosted their target price on Beta Bionics from $23.00 to $28.00 and gave the company a “buy” rating in a research note on Thursday, September 24th. Finally, William Blair assumed coverage on Beta Bionics in a research report on Friday, August 21st. They issued a “market perform” rating for the company. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $23.69.

Read Our Latest Stock Report on BBNX

About Beta Bionics

(Get Free Report)

Beta Bionics, Inc. develops medical technology for people with insulin-dependent diabetes. Its main product is the iLet Bionic Pancreas, an automated insulin-delivery system designed to help manage blood glucose levels with less manual adjustment by users. The iLet system combines an insulin pump with dosing software that works with a continuous glucose monitor. Rather than requiring users to enter detailed insulin settings, it is initialized using the user’s body weight and adjusts insulin delivery based on glucose readings.

Recommended Stories

Insider Buying and Selling by Quarter for Beta Bionics (NASDAQ:BBNX)

Receive News & Ratings for Beta Bionics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beta Bionics and related companies with MarketBeat.com's FREE daily email newsletter.